UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 375

Sortiert nach

Bebtelovimab: considerations for global access to treatments during a rapidly evolving pandemic

The Lancet infectious diseases, 2022-11, Vol.22 (11), p.1531-1531

2022

Volltextzugriff (PDF)

Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial

Lancet neurology, 2020-10, Vol.19 (10), p.814-825

2020

Volltextzugriff (PDF)

Clinical characteristics and treatment patterns of patients with episodic cluster headache: results from the United States, United Kingdom and Germany

Current medical research and opinion, 2023-12, Vol.39 (12), p.1637-1647

2023

Volltextzugriff (PDF)

The family tree

Nature (London), 2022-10

Nichols, Russell

2022

Volltextzugriff (PDF)

Effect of Bamlanivimab as Monotherapy or in Combination with Etesevimab or Sotrovimab on Persistently High Viral Load in Patients with Mild-to-Moderate COVID-19: A Randomized, Phase 2 BLAZE-4 Trial

Infectious diseases and therapy, 2024-02, Vol.13 (2), p.401-411

2024

Volltextzugriff (PDF)

Galcanezumab in Patients with Multiple Previous Migraine Preventive Medication Category Failures: Results from the Open-Label Period of the CONQUER Trial

Advances in therapy, 2021-11, Vol.38 (11), p.5465-5483

2021

Volltextzugriff (PDF)

Trash can rap

Nature (London), 2020-07

Nichols, Russell

2020

Volltextzugriff (PDF)

Effects of Galcanezumab on Health-Related Quality of Life and Disability in Patients with Previous Failure of 2–4 Migraine Preventive Medication Categories: Results from a Phase IIIb Randomized, Placebo-Controlled, Multicenter Clinical Trial (CONQUER)

Clinical drug investigation, 2022-03, Vol.42 (3), p.263-275

2022

Volltextzugriff (PDF)

Annual indirect cost savings in patients with episodic or chronic migraine: post-hoc analyses from multiple galcanezumab clinical trials

Journal of medical economics, 2022-12, Vol.25 (1), p.630-639

2022

Volltextzugriff (PDF)

Benefit–Risk Assessment of Galcanezumab Versus Placebo for the Treatment of Episodic and Chronic Migraine Using the Metrics of Number Needed to Treat and Number Needed to Harm

Advances in therapy, 2021-08, Vol.38 (8), p.4442-4460

2021

Volltextzugriff (PDF)

Reductions in acute medication use and healthcare resource utilization in patients with chronic migraine: a secondary analysis of a phase 3, randomized, double-blind, placebo-controlled study of galcanezumab with open-label extension (REGAIN)

Journal of medical economics, 2022-12, Vol.25 (1), p.1030-1038

2022

Volltextzugriff (PDF)

Migraine-Specific Quality-of-Life Questionnaire (MSQ) Version 2.1 Score Improvement in Japanese Patients with Episodic Migraine by Galcanezumab Treatment: Japan Phase 2 Study

Journal of pain research, 2020-01, Vol.13, p.3531-3538

2020

Volltextzugriff (PDF)

Correction to: Effects of Galcanezumab on Health-Related Quality of Life and Disability in Patients with Previous Failure of 2–4 Migraine Preventive Medication Categories: Results from a Phase IIIb Randomized, Placebo-Controlled, Multicenter Clinical Trial (CONQUER)

Clinical drug investigation, 2022-03, Vol.42 (3), p.277-277

2022

Volltextzugriff (PDF)

Patient-Reported Outcomes for Migraine in the US and Europe: Burden Associated with Multiple Preventive Treatment Failures

ClinicoEconomics and outcomes research, 2021-01, Vol.13, p.647-660

2021

Volltextzugriff (PDF)

Treatment patterns and predictors of costs among patients with migraine: evidence from the United States medical expenditure panel survey

Journal of medical economics, 2019-09, Vol.22 (9), p.849-858

2019

Volltextzugriff (PDF)

A real-world analysis of patient-reported outcomes in patients with migraine by preventive treatment eligibility status in the US and Europe

Journal of patient-reported outcomes, 2020-07, Vol.4 (1), p.53-53, Article 53

2020

Volltextzugriff (PDF)

Bamlanivimab and Etesevimab Improve Symptoms and Associated Outcomes in Ambulatory Patients at Increased Risk for Severe Coronavirus Disease 2019: Results From the Placebo-Controlled Double-Blind Phase 3 BLAZE-1 Trial

Open forum infectious diseases, 2022-05, Vol.9 (5), p.ofac172-ofac172

2022

Volltextzugriff (PDF)

Letter to the editor regarding European Headache Federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention

Journal of headache and pain, 2019-03, Vol.20 (1), p.22-22, Article 22

2019

Volltextzugriff (PDF)

Assessment of the Safety and Efficacy of Pre-emptive Use of Extended-release Buprenorphine for Mouse Laparotomy

Journal of the American Association for Laboratory Animal Science, 2022-07, Vol.61 (4), p.381-387, Article 381

2022

Volltextzugriff (PDF)

Next-Generation Sequencing-Based Identification of Enterobacter hormaechei as Causative Agent of High Mortality Disease in NOD.Cg- Prkdc scid Il2rg tm1Wjl /SzJ (NSG) Mice

Toxicologic pathology, 2024-01, Vol.52 (1), p.67-80

2024

Volltextzugriff (PDF)

A Real‐World Analysis of Patient Characteristics, Treatment Patterns, and Level of Impairment in Patients With Migraine Who are Insufficient Responders vs Responders to Acute Treatment

Headache, 2020-07, Vol.60 (7), p.1325-1339

2020

Volltextzugriff (PDF)

Analysis of Initial Nonresponders to Galcanezumab in Patients With Episodic or Chronic Migraine: Results From the EVOLVE‐1, EVOLVE‐2, and REGAIN Randomized, Double‐Blind, Placebo‐Controlled Studies

Headache, 2019-02, Vol.59 (2), p.192-204

2019

Volltextzugriff (PDF)

Changes in patient functioning and disability: results from a phase 3, double-blind, randomized, placebo-controlled clinical trial evaluating galcanezumab for chronic migraine prevention (REGAIN)

Quality of life research, 2021-01, Vol.30 (1), p.105-115

2021

Volltextzugriff (PDF)

Proliferation of Escherichia coli O157:H7 in Soil-Substitute and Hydroponic Microgreen Production Systems

Journal of food protection, 2015-10, Vol.78 (10), p.1785

2015

Volltextzugriff (PDF)

Registry-based, prospective, observational studies to assess maternal, fetal, and infant outcomes following exposure to migraine treatments, including galcanezumab

Journal of the neurological sciences, 2021-10, Vol.429, p.119266, Article 119266

2021

Volltextzugriff (PDF)

1 – 25 von 375

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(320)
Mit Volltextzugriff
(302)

Publikationsform

5 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Bebtelovimab: considerations for global access to treatments during a rapidly evolving pandemic

Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial

Clinical characteristics and treatment patterns of patients with episodic cluster headache: results from the United States, United Kingdom and Germany

The family tree

Effect of Bamlanivimab as Monotherapy or in Combination with Etesevimab or Sotrovimab on Persistently High Viral Load in Patients with Mild-to-Moderate COVID-19: A Randomized, Phase 2 BLAZE-4 Trial

Galcanezumab in Patients with Multiple Previous Migraine Preventive Medication Category Failures: Results from the Open-Label Period of the CONQUER Trial

Trash can rap

Effects of Galcanezumab on Health-Related Quality of Life and Disability in Patients with Previous Failure of 2–4 Migraine Preventive Medication Categories: Results from a Phase IIIb Randomized, Placebo-Controlled, Multicenter Clinical Trial (CONQUER)

Annual indirect cost savings in patients with episodic or chronic migraine: post-hoc analyses from multiple galcanezumab clinical trials

Benefit–Risk Assessment of Galcanezumab Versus Placebo for the Treatment of Episodic and Chronic Migraine Using the Metrics of Number Needed to Treat and Number Needed to Harm

Reductions in acute medication use and healthcare resource utilization in patients with chronic migraine: a secondary analysis of a phase 3, randomized, double-blind, placebo-controlled study of galcanezumab with open-label extension (REGAIN)

Migraine-Specific Quality-of-Life Questionnaire (MSQ) Version 2.1 Score Improvement in Japanese Patients with Episodic Migraine by Galcanezumab Treatment: Japan Phase 2 Study

Correction to: Effects of Galcanezumab on Health-Related Quality of Life and Disability in Patients with Previous Failure of 2–4 Migraine Preventive Medication Categories: Results from a Phase IIIb Randomized, Placebo-Controlled, Multicenter Clinical Trial (CONQUER)

Patient-Reported Outcomes for Migraine in the US and Europe: Burden Associated with Multiple Preventive Treatment Failures

Treatment patterns and predictors of costs among patients with migraine: evidence from the United States medical expenditure panel survey

A real-world analysis of patient-reported outcomes in patients with migraine by preventive treatment eligibility status in the US and Europe

Bamlanivimab and Etesevimab Improve Symptoms and Associated Outcomes in Ambulatory Patients at Increased Risk for Severe Coronavirus Disease 2019: Results From the Placebo-Controlled Double-Blind Phase 3 BLAZE-1 Trial

Letter to the editor regarding European Headache Federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention

Assessment of the Safety and Efficacy of Pre-emptive Use of Extended-release Buprenorphine for Mouse Laparotomy

Next-Generation Sequencing-Based Identification of Enterobacter hormaechei as Causative Agent of High Mortality Disease in NOD.Cg- Prkdc scid Il2rg tm1Wjl /SzJ (NSG) Mice

A Real‐World Analysis of Patient Characteristics, Treatment Patterns, and Level of Impairment in Patients With Migraine Who are Insufficient Responders vs Responders to Acute Treatment

Analysis of Initial Nonresponders to Galcanezumab in Patients With Episodic or Chronic Migraine: Results From the EVOLVE‐1, EVOLVE‐2, and REGAIN Randomized, Double‐Blind, Placebo‐Controlled Studies

Changes in patient functioning and disability: results from a phase 3, double-blind, randomized, placebo-controlled clinical trial evaluating galcanezumab for chronic migraine prevention (REGAIN)

Proliferation of Escherichia coli O157:H7 in Soil-Substitute and Hydroponic Microgreen Production Systems

Registry-based, prospective, observational studies to assess maternal, fetal, and infant outcomes following exposure to migraine treatments, including galcanezumab

Suchergebnisse filtern